H Lundbeck A/S (HLUN A.CO) stock: key figures, P/E, revenue and dividend

Health Care · Denmark · ISIN DK0061804697

Price
44.90 DKK
Market cap
44.54 bn DKK
P/E (2025)
13.95
P/S (2025)
1.83
Dividend yield
2.56 %
Net margin
13.11 %
Return on equity (ROE)
12.82 %
Return on assets (ROA)
5.91 %

H Lundbeck A/S financials

Fiscal year20242025
Revenue22.00 bn DKK24.35 bn DKK
Gross profit17.77 bn DKK19.38 bn DKK
Operating income3.27 bn DKK6.34 bn DKK
Net income3.14 bn DKK3.19 bn DKK
Diluted EPS – continuing operations3.17 DKK3.22 DKK

Full history since 2004, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About H Lundbeck A/S

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 19.10.2026. Details in the risk notice.

H Lundbeck A/S stock (HLUN A.CO): P/E, revenue, dividend | finmetric